Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INV 347

Next Previous
Drug Profile

INV 347

Alternative Names: INV-347; NN-9441

Latest Information Update: 09 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inversago Pharma
  • Class Obesity therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 31 Jan 2024 Phase-I clinical trials in Obesity (PO) (Novo Nordisk pipeline, April 2024)
  • 31 Dec 2023 Preclinical trials in Obesity in Denmark (PO) before December 2023
  • 01 Sep 2023 Inversago Pharma has been acquired by Novo Nordisk (Novo Nordisk, Form 20-F 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top